Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
502.00    -3.00 (-0.59%)
Bid:
501.50
Ask:
503.00
Spread: 1.50 (0.299%)
Market Cap: £2.22b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

8 Feb 2018 07:00

8 February 2018 – Tate & Lyle PLC

TRADING STATEMENT

Tate & Lyle issues the following trading statement for the three months ended 31 December 2017.

The Group saw volume momentum in its Speciality Food Ingredients and Bulk Ingredients divisions and remains on track to deliver progress in adjusted profit before tax in constant currency for the year ending 31 March 2018, in line with guidance.

In Speciality Food Ingredients, the core business delivered good volume growth, including a continuation of modest volume growth in North America. In Food Systems, profit improved although volume was lower. SPLENDA ® Sucralose performed as anticipated with profit in line with the comparative period. In the division overall, decisions taken in the first half, particularly to invest behind the longer term development of the business, will moderate profit growth in the second half.

In Bulk Ingredients, sweetener volume in North America grew and profit growth is currently expected to be robust for the financial year ending 31 March 2018. The 2018 calendar year bulk sweetener pricing round is now substantially complete with margins broadly in line with the previous year.

END

A conference call will be held today at 08.00am GMT, hosted by Javed Ahmed, Chief Executive and Nick Hampton, Chief Executive designate and Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666

Password: Tate & Lyle

A replay of this call will be available after the end of the live call for 14 days until 22 February 2018.

UK replay number: 0208 196 1998

Replay access PIN: 6346734

For more information contact Tate & Lyle PLC:

Christopher Marsh, Group VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations at more than 30 facilities worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA ® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2017, Tate & Lyle sales totalled £2.8 billion. For more information, please visit http://www.tateandlyle.com .

SPLENDA ® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180207005974/en/

Copyright Business Wire 2018

Date   Source Headline
5th Aug 20204:30 pmRNSDirector/PDMR Shareholding
3rd Aug 20202:00 pmRNSTotal Voting Rights
23rd Jul 20201:00 pmRNSResult of AGM
23rd Jul 20207:00 amRNSTrading Statement
2nd Jul 20205:45 pmRNSBlock listing Interim Review
1st Jul 20203:06 pmRNSRights attaching to the listed share capital
1st Jul 20203:05 pmRNSTotal Voting Rights
9th Jun 20203:00 pmRNSAnnual Financial Report
2nd Jun 20203:56 pmRNSDirector/PDMR Shareholding
21st May 20207:00 amRNSFinal Results
4th May 20207:00 amRNSTrading Update
1st May 20203:27 pmRNSTotal Voting Rights
3rd Apr 202011:00 amRNSDirector Declaration
1st Apr 202012:26 pmRNSTotal Voting Rights
6th Feb 20207:00 amRNSTrading Statement
30th Jan 202011:45 amRNSDirector/PDMR Shareholding
7th Jan 20202:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202012:41 pmRNSBlock listing Interim Review
19th Dec 20192:00 pmRNSDirector/PDMR Shareholding
7th Nov 20197:00 amRNSHalf-year Report
3rd Oct 20193:06 pmRNSHolding(s) in Company
1st Oct 201910:14 amRNSTotal Voting Rights
19th Sep 20197:00 amRNSFULL PENSION SCHEME BUY-IN WITH LEGAL & GENERAL
6th Sep 201910:15 amRNSDirector/PDMR Shareholding
30th Aug 201912:00 pmRNSDirector Declaration
21st Aug 201910:00 amRNSDirector/PDMR Shareholding
5th Aug 20193:00 pmRNSIssue of Debt
1st Aug 20192:00 pmRNSTotal Voting Rights
25th Jul 201912:58 pmRNSResult of AGM
18th Jul 20193:00 pmRNSDirector/PDMR Shareholding
17th Jul 20197:02 amRNSChange to Executive Committee
1st Jul 201912:40 pmRNSBlock listing Interim Review
1st Jul 201912:38 pmRNSTotal Voting Rights
1st Jul 201912:00 pmRNSDirector/PDMR Shareholding
10th Jun 201911:30 amRNSAnnual Financial Report
5th Jun 20199:52 amRNSHolding(s) in Company
5th Jun 20199:34 amRNSDirector/PDMR Shareholding
3rd Jun 201910:42 amRNSTotal Voting Rights
29th May 20194:00 pmRNSDirector/PDMR Shareholding
28th May 20194:12 pmRNSDirector/PDMR Shareholding
23rd May 20197:00 amRNSFinal Results
9th May 201911:00 amRNSDirectorate Change
1st May 201910:00 amRNSTotal Voting Rights
1st Apr 20194:17 pmBUSTotal Voting Rights
1st Apr 20193:45 pmBUSHolding(s) in Company
1st Mar 201911:21 amBUSTotal Voting Rights
27th Feb 20191:00 pmBUSHolding(s) in Company
7th Feb 20197:00 amBUSTrading Statement
1st Feb 201911:40 amBUSTotal Voting Rights
3rd Jan 20192:00 pmBUSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.